Summary
For Year 2026-27, Novelix Pharmaceuticals reports the following shareholding: Total Promoters at 49.43%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 0%, Domestic Institutional Investors at 0%, and Retail at 50.57%. This breakdown provides a quick snapshot of ownership distribution for Novelix Pharmaceuticals in 2026-27.
Novelix Pharmaceuticals FAQs
As of 04-2026, the promoter shareholding in Novelix Pharmaceuticals stands at 49.43% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Novelix Pharmaceuticals is 0% and 0% respectively.
The retail shareholding of the Novelix Pharmaceuticals is 50.57%.
Changes in shareholding patterns of Novelix Pharmaceuticals can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Novelix Pharmaceuticals are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
Novelix Pharmaceuticals Associated Pages
